Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial

AIM: To test the efficacy and safety of osmotic release oral system (OROS) methylphenidate (MPH) in doses up to 180 mg/day to treat attention deficit hyperactivity disorder (ADHD) and prevent any drug relapse in individuals with a co-diagnosis of ADHD and amphetamine dependence. DESIGN: Randomized p...

Descripción completa

Detalles Bibliográficos
Autores principales: Konstenius, Maija, Jayaram-Lindström, Nitya, Guterstam, Joar, Beck, Olof, Philips, Björn, Franck, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226329/
https://www.ncbi.nlm.nih.gov/pubmed/24118269
http://dx.doi.org/10.1111/add.12369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226329/
https://www.ncbi.nlm.nih.gov/pubmed/24118269
http://dx.doi.org/10.1111/add.12369

Ejemplares similares